Jos. L. J. van der Velden

Jos. L. J. van der Velden

Auto-generated profile, based on publicly available information

Jos. L. J. van der Velden

Department of Pathology and Laboratory Medicine, University of Vermont Cancer Center, Larner College of Medicine, Burlington, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
RLRamon C. J. Langen
Ramon C. J. Langen
JVJos L. J. van der Velden
Jos L. J. van der Velden
ASAnnemie M. W. J. Schols
Annemie M. W. J. Schols
MKMarco C. J. M. Kelders
Marco C. J. M. Kelders
EWEmiel F. M. Wouters
Emiel F. M. Wouters
YJYvonne M. W. Janssen‐Heininger
Yvonne M. W. Janssen‐Heininger

9 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
VAVikas Anathy
Vikas Anathy
KLKarolyn G. Lahue
Karolyn G. Lahue
DCDavid G. Chapman
David G. Chapman
SCShi B. Chia
Shi B. Chia
DCDylan T. Casey
Dylan T. Casey
YJYvonne Janssen-Heininger
Yvonne Janssen-Heininger

2 September 2016 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
JVJos L. J. van der Velden
Jos L. J. van der Velden
YYYing Ye
Ying Ye
JNJames D. Nolin
James D. Nolin
SHSidra M. Hoffman
Sidra M. Hoffman
DCDavid G. Chapman
David G. Chapman
PSPeter H. Schafer
Peter H. Schafer
Background: Lung remodeling and pulmonary fibrosis are serious, life‐threatening conditions resulting from diseases such as chronic severe asthma and idiopathic pulmonary fibrosis (IPF). Preclinical evidence suggests that JNK enzyme function is required for key steps in the pulmonary fibrotic process. However, a selective JNK inhibitor has not been investigated in translational models of lung fibrosis with clinically relevant biomarkers, or in IPF patients.Methods: The JNK inhibitor CC‐930 was evaluated in the house dust mite‐induced fibrotic airway mouse model, in a phase I healthy volunteer pharmacodynamic study, and subsequently in a phase II multicenter study of mild/moderate IPF (n = 28), with a 4‐week, placebo‐controlled, double‐blind, sequential ascending‐dose period (50 mg QD, 100 mg QD, 100 mg BID) and a 52‐week open‐label treatment‐extension period.Results: In the preclinical model, CC‐930 attenuated collagen 1A1 gene expression, peribronchiolar collagen deposition, airway mucin MUC5B expression in club cells, and MMP‐7 expression in lung, bronchoalveolar lavage fluid, and serum. In the phase I study, CC‐930 reduced c‐Jun phosphorylation induced by UV radiation in skin. In the phase II IPF study, there was a CC‐930 dose‐dependent trend in reduction of MMP‐7 and SP‐D plasma protein levels. The most commonly reported adverse events were increased ALT, increased AST, and upper respiratory tract infection (six subjects each, 21.4 %). A total of 13 subjects (46.4 %) experienced adverse events that led to discontinuation of study drug. Nine out of 28 subjects experienced progressive disease in this study. The mean FVC (% predicted) declined after 26–32 weeks at doses of 100 mg QD and 100 mg BID. Changes in MMP‐7, SP‐D, and tenascin‐C significantly correlated with change in FVC (% predicted).Conclusions: These results illustrate JNK enzymatic activity involvement during pulmonary fibrosis, and support systemic biomarker use for tracking disease progression and the potential clinical benefit of this novel intervention in IPF.Trial registration ClinicalTrials.gov NCT01203943

1 April 2008 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
JAJohn F. Alcorn
John F. Alcorn
AGAmy S. Guala
Amy S. Guala
JVJos van der Velden
Jos van der Velden
BMBrian McElhinney
Brian McElhinney
CICharles G. Irvin
Charles G. Irvin
YJYvonne Janssen-Heininger
Yvonne Janssen-Heininger
Transforming growth factor β1 (TGF-β1) is a cardinal cytokine in the pathogenesis of airway remodeling, and promotes epithelial-to-mesenchymal transition (EMT). As a molecular interaction between TGF-β1 and Jun N-terminal kinase (JNK) has been demonstrated, the goal of this study was to elucidate whether JNK plays a role in TGF-β1-induced EMT. Primary cultures of mouse tracheal epithelial cells (MTEC) from wild-type, JNK1–/– or JNK2–/– mice were comparatively evaluated for their ability to undergo EMT in response to TGF-β1. Wild-type MTEC exposed to TGF-β1 demonstrated a prominent induction of mesenchymal mediators and a loss of epithelial markers, in conjunction with a loss of trans-epithelial resistance (TER). Significantly, TGF-β1-mediated EMT was markedly blunted in epithelial cells lacking JNK1, while JNK2–/– MTEC underwent EMT in response to TGF-β1 in a similar way to wild-type cells. Although Smad2/3 phosphorylation and nuclear localization of Smad4 were similar in JNK1–/– MTEC in response to TGF-β1, Smad DNA-binding activity was diminished. Gene expression profiling demonstrated a global suppression of TGF-β1-modulated genes, including regulators of EMT in JNK1–/– MTEC, in comparison with wild-type cells. In aggregate, these results illuminate the novel role of airway epithelial-dependent JNK1 activation in EMT.

1 May 2009 in Proceedings of the American Thoracic Society
Verified
Journal Article
Closed access
YJYvonne Janssen-Heininger
Yvonne Janssen-Heininger
MPMatthew E Poynter
Matthew E Poynter
SAScott W. Aesif
Scott W. Aesif
CPCristen Pantano
Cristen Pantano
JAJennifer L. Ather
Jennifer L. Ather
AVAlbert van der Vliet
Albert van der Vliet
A wealth of recent studies points to the importance of airway epithelial cells in the orchestration of inflammatory responses in the allergic inflamed lung. Studies also point to a role of oxidative stress in the pathophysiology of chronic inflammatory diseases. This article provides a perspective on the significance of airway epithelial cells in allergic inflammation, and reviews the relevance of the transcription factor, nuclear factor κB, herein. We also provide the reader with a perspective on the role that oxidants can play in lung homeostasis, and address the concept of “redox biology.” In addition, we review recent evidence that highlights potential inhibitory roles of oxidants on nuclear factor κB activation and inflammation, and discuss recent assays that have become available to probe the functional roles of oxidants in lung biology.

1 September 2002 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
RLRamon C. J. Langen
Ramon C. J. Langen
ASAnnemie M. W. J. Schols
Annemie M. W. J. Schols
MKMarco C. J. M. Kelders
Marco C. J. M. Kelders
JVJos L. J. van der Velden
Jos L. J. van der Velden
EWEmiel F. M. Wouters
Emiel F. M. Wouters
YJYvonne M. W. Janssen-Heininger
Yvonne M. W. Janssen-Heininger
Muscle wasting accompanies diseases that are associated with chronic elevated levels of circulating inflammatory cytokines and oxidative stress. We previously demonstrated that tumor necrosis factor-α (TNF-α) inhibits myogenic differentiation via the activation of nuclear factor-κB (NF-κB). The goal of the present study was to determine whether this process depends on the induction of oxidative stress. We demonstrate here that TNF-α causes a decrease in reduced glutathione (GSH) during myogenic differentiation of C2C12 cells, which coincides with an elevated generation of reactive oxygen species. Supplementation of cellular GSH with N-acetyl-l-cysteine (NAC) did not reverse the inhibitory effects of TNF-α on troponin I promoter activation and only partially restored creatine kinase activity in TNF-α-treated cells. In contrast, the administration of NAC before treatment with TNF-α almost completely restored the formation of multinucleated myotubes. NAC decreased TNF-α-induced activation of NF-κB only marginally, indicating that the redox-sensitive component of the inhibition of myogenic differentiation by TNF-α occurred independently, or downstream of NF-κB. Our observations suggest that the inhibitory effects of TNF-α on myogenesis can be uncoupled in a redox-sensitive component affecting myotube formation and a redox independent component affecting myogenic protein expression.